Private financing and debt resolution concluded by Revive Therapeutics in first phase of private placement and debt settlement
Revive Therapeutics Ltd., a life sciences company focused on the research and development of cannabinoid, psychedelics, and infectious diseases programs, has announced the closure of the first tranche of its private placement offering. The purpose of this offering, which took place in August 2025, was to raise gross proceeds primarily for working capital and to pay certain trade payables, with part of the proceeds used to settle outstanding debt by issuing securities instead of using cash, thereby preserving the company’s cash for ongoing operations.
The private placement involved issuing units at $0.021 each. Each unit consisted of one common share and one warrant with an exercise price of $0.05. The first tranche closed on August 11, 2025, raising $60,900 through the issuance of 2.9 million units and settling $67,400 of debt by issuing 3.2 million units at the same price.
The funds raised will be utilised for working capital to support ongoing business needs, payment of certain trade payables, and the settlement of outstanding debt via issuance of securities to conserve cash for operations.
Michael Frank, the Chief Executive Officer of Revive Therapeutics Ltd., can be contacted at Tel: 1 888 901 0036 or via email at [email protected].
It is important to note that this press release contains forward-looking information regarding the Company's programs. Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated.
Each compensation option entitles the dealer to purchase one unit at a price of $0.05 for 18 months. Each warrant entitles the holder to acquire one common share at an exercise price of $0.05 for 36 months. All securities issued are subject to a hold period of four months and one day expiring on December 9, 2025.
Reference is made to the risk factors disclosed under the heading "Risk Factors" in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025, which is available on the Company's profile at www.sedarplus.ca.
For more information about Revive Therapeutics Ltd., please visit their website at www.revivethera.com.
[1] Source [2] Source [3] Source
Read also:
- Imported goods from China continue to evade US tariffs
- Study by the Centre for Chronic Disease Control (CCDC) Shows Promise of Two-drug Combinations for Enhancing Blood Pressure Management in Individuals of Indian Origin
- Navigating Trusts for Entrepreneurs: A Comprehensive Legal Handbook
- June's financial results reveal a shortfall of $2 billion in the account's balance.
